Senhwa Biosciences

Senhwa Biosciences is a clinical-stage oncology company developing innovative small molecule inhibitors of the DNA Damage Response (DDR), with its lead asset, silmitasertib (CX-4945), targeting Casein Kinase 2 (CK2). The company has advanced multiple programs into mid-stage clinical trials, exploring both monotherapy and combination strategies in cholangiocarcinoma, medulloblastoma, and COVID-19. Its strategy is to exploit tumor-specific genetic vulnerabilities to achieve synthetic lethality and enhance the efficacy of existing cancer therapies, positioning itself in the high-growth targeted oncology and DDR inhibitor space.

Platform focused on discovering small molecule inhibitors of novel targets within the DNA Damage Response (DDR) network, with lead expertise in Casein Kinase 2 (CK2) inhibition to induce synthetic lethality and chemo/radiosensitization in cancer cells.

Senhwa is a first-mover in clinical CK2 inhibition but faces indirect competition from established PARP inhibitors and later-stage ATR/DNA-PK inhibitors. Its differentiation hinges on demonstrating compelling efficacy in niche, high-unmet-need indications like cholangiocarcinoma and medulloblastoma to attract partnership interest.